Iqvia Holdings Inc Stock Nyse
Equities
US74876Y1010
Biotechnology & Medical Research
Sales 2024 * | 15.53B 21.21B | Sales 2025 * | 16.68B 22.78B | Capitalization | 42.75B 58.39B |
---|---|---|---|---|---|
Net income 2024 * | 1.32B 1.8B | Net income 2025 * | 1.58B 2.16B | EV / Sales 2024 * | 3.53 x |
Net Debt 2024 * | 12.06B 16.47B | Net Debt 2025 * | 11.62B 15.87B | EV / Sales 2025 * | 3.26 x |
P/E ratio 2024 * |
32.2
x | P/E ratio 2025 * |
26.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.76% |
Latest transcript on Iqvia Holdings Inc
Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 16-10-02 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 20-07-31 |
James Berkshire
COO | Chief Operating Officer | 51 | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 16-10-02 |
Colleen Goggins
BRD | Director/Board Member | 68 | 17-07-26 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 16-10-02 |
1st Jan change | Capi. | |
---|---|---|
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B | |
-16.98% | 10.07B |